Arena Pharmaceuticals, Inc (NASDAQ:ARNA)’s Belviq finally enters the anti-obesity arena
Arena Pharmaceuticals, Inc (NASDAQ:ARNA)’s long awaited anti-obesity drug, Belviq, has finally been launched and the wars are sure to start heating up. To date, VIVUS Inc was the only company operating that space. However, Arena’s entry on to the scene has automatically tilted the scales a bit. Vivus has not had a very good run with its own drug and it’s only a matter of time before the winner emerges. In this case, the early bird may not necessarily get the worm.
Keep Arena stock on your radar
Belviq is expected to garner more revenue for ARNA and hopefully that will also attract a flood of investors to its stock. There was no phenomenal rise in the company’s share prices post announcement of the Belviq launch. However, the expectation is that once the sales figures for the quarter come in, the company is sure to take off and make sizeable returns.
Investors interested in biopharmaceutical companies should keep a keen eye on the Arena stock and cash-in at the opportune moment.
Patients can now get the prescription drug, Belviq, in U.S pharmacies. The U.S FDA gave its nod for the drug on 27 June 2012. At that point of time, it was the very first weight-loss drug to gain approval, in 13 years. Eisai will be responsible for marketing and distribution of the drug and the drug-maker has achieved a $65M milestone from Eisai. Any extensions could stretch Belviq’s patent term to 2026.
About the drug
Belviq is used for weight-loss in two different groups. Either for those who are already obese or overweight. In order to be eligible to be prescribed the drug, they should be suffering from at least 1 weight-related condition like high blood pressure, Type 2 Diabetes or high cholesterol. Arena’s Belviq has now taken flight. Only time will tell whether it will be able to maintain a steady flight path.